Detalles de la búsqueda
1.
Prospective evaluation of the tolerability and efficacy of niraparib dosing based on baseline body weight and platelet count: Results from the PRIMA/ENGOT-OV26/GOG-3012 trial.
Cancer
; 129(12): 1846-1855, 2023 06 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-37060236
2.
Pharmacogenetics as a predictor chemotherapy induced peripheral neuropathy in gynecologic cancer patients treated with Taxane-based chemotherapy.
Gynecol Oncol
; 168: 114-118, 2023 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36434945
3.
High serum levels of inflammatory markers are associated with early recurrence in patients with high-grade serous ovarian cancer after platinum therapy.
Gynecol Oncol
; 179: 1-8, 2023 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-37862814
4.
Randomized phase II trial of farletuzumab plus chemotherapy versus placebo plus chemotherapy in low CA-125 platinum-sensitive ovarian cancer.
Gynecol Oncol
; 170: 300-308, 2023 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-36758420
5.
A plain language summary of results from the GARNET study of dostarlimab in patients with endometrial cancer.
Future Oncol
; 19(25): 1709-1714, 2023 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-37381977
6.
A phase III, multicenter, randomized study of olvimulogene nanivacirepvec followed by platinum-doublet chemotherapy and bevacizumab compared with platinum-doublet chemotherapy and bevacizumab in women with platinum-resistant/refractory ovarian cancer.
Int J Gynecol Cancer
; 33(9): 1458-1463, 2023 09 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-37666539
7.
Clinical calculator redefines prognosis for high-risk early-stage ovarian cancers and potential to guide treatment in the adjuvant setting.
Gynecol Oncol
; 167(2): 205-212, 2022 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-36055814
8.
Are There Survival Differences Between Women with Equivalent Residual Disease After Interval Cytoreductive Surgery Compared with Primary Cytoreductive Surgery for Advanced Ovarian and Peritoneal Cancer?
Ann Surg Oncol
; 28(7): 3605-3615, 2021 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-33155151
9.
Standardization of lower extremity quantitative lymphedema measurements and associated patient-reported outcomes in gynecologic cancers.
Gynecol Oncol
; 160(2): 625-632, 2021 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-33158510
10.
Gemogenovatucel-T (Vigil) immunotherapy as maintenance in frontline stage III/IV ovarian cancer (VITAL): a randomised, double-blind, placebo-controlled, phase 2b trial.
Lancet Oncol
; 21(12): 1661-1672, 2020 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-33271095
11.
EMR 20006-012: A phase II randomized double-blind placebo controlled trial comparing the combination of pimasertib (MEK inhibitor) with SAR245409 (PI3K inhibitor) to pimasertib alone in patients with previously treated unresectable borderline or low grade ovarian cancer.
Gynecol Oncol
; 156(2): 301-307, 2020 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-31870556
12.
Long term survival outcomes of stage I mucinous ovarian cancer - A clinical calculator predictive of chemotherapy benefit.
Gynecol Oncol
; 159(1): 118-128, 2020 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-32828578
13.
A 73-gene proliferative transcriptomic signature predicts uterine serous carcinoma patient survival and response to primary therapy.
Gynecol Oncol
; 157(2): 340-347, 2020 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-32067813
14.
A combined score of clinical factors and serum proteins can predict time to recurrence in high grade serous ovarian cancer.
Gynecol Oncol
; 152(3): 574-580, 2019 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-30578005
15.
Atypical Presentations of Molar Pregnancy: Diagnostic Roles of Imaging, ß-Human Chorionic Gonadotropin Measurement, and p57 Immunostaining.
J Ultrasound Med
; 35(3): 643-9, 2016 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-26860483
16.
Phase II study of the PI3K inhibitor pilaralisib (SAR245408; XL147) in patients with advanced or recurrent endometrial carcinoma.
Gynecol Oncol
; 136(2): 246-53, 2015 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-25528496
17.
A phase 1 open-label, sequential dose-escalation study investigating the safety, tolerability, and pharmacokinetics of intravenous TLC388 administered to patients with advanced solid tumors.
Invest New Drugs
; 32(3): 445-51, 2014 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-24271274
18.
Twelve serum proteins progressively increase with disease stage in squamous cell cervical cancer patients.
Int J Gynecol Cancer
; 24(6): 1085-92, 2014 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-24905620
19.
Phase I Trial of First-line Bintrafusp Alfa in Patients with Locally Advanced or Persistent/Recurrent/Metastatic Cervical Cancer.
Clin Cancer Res
; 30(5): 975-983, 2024 03 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-38165683
20.
Serum Proteomic Signatures in Cervical Cancer: Current Status and Future Directions.
Cancers (Basel)
; 16(9)2024 Apr 24.
Artículo
en Inglés
| MEDLINE | ID: mdl-38730581